A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum-Resistant or Ineligible Ovarian and Related Cancers with Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)
Details
Age
Adult
Type of Study
Treatment
Locations
University of Colorado Hospital
Principal Investigator
Bradley Corr, MD
Study ID
Protocol Number: 21-4100
More information available at ClinicalTrials.gov: NCT04092270
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers